4.3. Analysis.
Comparison 4: Gemcitabine versus Bacillus Calmette‐Guérin [BCG] for recurrent (one‐course BCG failure) high‐risk non‐muscle invasive bladder cancer, Outcome 3: Grade III–V adverse events
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.